Suchen
Abcellera Biologics Inc
ABCLZur Watchlist hinzufügen
7.600USD
-0.250-3.18%
Handelsschluss 07/01, 16:00（ET）Kurse um 15 Minuten verzögert
2.31BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Abcellera Biologics Inc Unternehmen
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
Abcellera Biologics Inc Informationen
BörsenkürzelABCL
Name des UnternehmensAbcellera Biologics Inc
IPO-datumDec 11, 2020
CEOHansen (Carl L.G)
Anzahl der mitarbeiter596
WertpapierartOrdinary Share
GeschäftsjahresendeDec 11
Addresse150 W 4Th Avenue
StadtVANCOUVER
BörseNASDAQ OMX - NASDAQ BASIC
LandCanada
PostleitzahlV5Y 1G6
Telefon16045599005
Websitehttps://www.abcellera.com/
BörsenkürzelABCL
IPO-datumDec 11, 2020
CEOHansen (Carl L.G)
Führungskräfte von Abcellera Biologics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
576.56K
+43.36%
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Stephen Quake
Mr. Stephen Quake
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
576.56K
+43.36%
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Abcellera Biologics Inc?
Die fünf größten Anteilseigner von Abcellera Biologics Inc sind: Dr. Veronique Lecault, Ph.D.
Wie viele Institutionen halten Anteile an Abcellera Biologics Inc (ABCL)?
Mit Stand vom 2026Q1 halten 323 Institutionen Anteile an Abcellera Biologics Inc, mit einem Gesamtmarktwert von etwa 131.69M, was 43.14% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -19217264.00 gestiegen.
Was ist die größte Einnahmequelle von Abcellera Biologics Inc?
Am 2026Q1 erzielte das Geschäft mit Licensing revenue für Abcellera Biologics Inc den höchsten Umsatz in Höhe von 46.92M, was 62.45% des Gesamtumsatzes entspricht.